A Trial With Chemotherapy, Immunotherapy, and Radiotherapy for Patients With Newly Diagnosed Stage IV Small Cell Lung Cancer
Phase II Trial of Platinum-Etoposide Chemotherapy and Durvalumab (MEDI4736) With Sub-Ablative SBRT in Patients With Newly Diagnosed Stage IV Small Cell Lung Cancer
Sponsor: Weill Medical College of Cornell University
Terminated
The study was terminated early due to low accrual.
Other terminated trials from Weill Medical College of Cornell University
- Epilepsy · Apr 2025
- Anxiety Disorders · Phase NA · Nov 2024
- Myeloproliferative Neoplasm · Phase PHASE2 · Jul 2024
- Infertility, Male · Phase PHASE2 · May 2024
- Anxiety · Apr 2024
See all terminations from Weill Medical College of Cornell University
Other Small-cell Lung Cancer trials with similar outcome
Listed as NCT04951115, this PHASE2 trial focuses on Small-cell Lung Cancer and remains terminated or withdrawn. Sponsored by Weill Medical College of Cornell University, it has been updated 6 times since 2021, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
6 versions recorded-
Dec 2024 — Present [monthly]
Terminated PHASE2
Status: Completed → Terminated
-
Sep 2024 — Dec 2024 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Aug 2023 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Sep 2022 — Aug 2023 [monthly]
Recruiting PHASE2
▶ Show 1 earlier version
-
Sep 2021 — Sep 2022 [monthly]
Recruiting PHASE2
First recorded
Jul 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Weill Medical College of Cornell University
For direct contact, visit the study record on ClinicalTrials.gov .